Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

This trial tests a combination of two targeted cancer drugs — adagrasib (which blocks a specific cancer gene mutation called KRAS G12C) and olaparib (which disrupts cancer cell DNA repair) — in people with advanced solid tumors. It focuses on pancreatic cancer, breast cancer, ovarian/uterine cancer, and a type of lung cancer with a specific co-mutation (KEAP1). **You may be eligible if...** - You are 18 or older with an advanced solid tumor that has the KRAS G12C gene mutation - Your cancer has progressed despite at least one prior standard treatment - You are in generally good health and able to care for yourself (good performance status) - Your cancer is unresectable (cannot be surgically removed) or has spread **You may NOT be eligible if...** - You have active, untreated brain metastases - You have had a heart attack, severe heart failure, or stroke within the last 6 months - You are pregnant or breastfeeding - You have active HIV, hepatitis B, or hepatitis C infection - You have had certain stomach/intestinal conditions that might affect how you absorb pills - You have had major surgery within 4 weeks of starting the study Talk to your doctor to see if this trial is right for you.